ARTICLE | Top Story

FLINTy reception for Intercept

November 8, 2014 3:04 AM UTC

Although a Bloomberg report on The Lancet's publication of data from the Phase II FLINT trial of obeticholic acid in non-alcoholic steatohepatitis (NASH) largely rehashed old ground, investors hammered shares of Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) on Friday. The stock finished the day off $74.39 (30%) to $172.59.

For the week, Intercept's market cap fell $1.7 billion to $3.7 billion. ...